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Abstract
Purpose: Transgenic mice expressing the polyoma middle T oncoprotein (PyMT) in the
mammary epithelium were explored by multimodal imaging to monitor longitudinally spontane-
ous tumor growth and response to chemotherapy.
Procedures: Positron emission tomography (PET) with 2-deoxy-2-[18F]fluoro-D-glucose
([18F]FDG) and 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT), single photon emission tomography
(SPECT) with [99mTc]TcO4 ([
99mTc]TEC), X-ray computed tomography, and fluorescent confocal
endomicroscopy (FCE) images were acquired during tumor progression in female PyMT mice.
Imaging with [18F]FDG and [99mTc]TEC was also performed in untreated, doxorubicin-treated,
and docetaxel-treated PyMT mice. Total tumor volumes were quantified. Tumors were collected
and macroscopic and histological examinations were performed.
Results: All PyMT mice developed multifocal tumors of the mammary epithelium that became
palpable at 8 weeks of age (W8). Computed tomography (CT) detected tumors at W14, while a
clear tumoral uptake of [99mTc]TEC and [18F]FDG was present as early as W6 and W8,
respectively. No contrast between mammary tumors and surrounding tissue was observed at
any stage with [18F]FLT. FCE detected an angiogenic switch at W10. Lung metastases were not
clearly evidenced by imaging. Doxorubicin and docetaxel treatments delayed tumor growth, as
shown by [18F]FDG and [99mTc]TEC, but tumor growth resumed upon treatment discontinuation.
Tumor growth fitted an exponential model with time constant rates of 0.315, 0.145, and
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0.212 week−1 in untreated, doxorubicin, and docetaxel groups, respectively.
Conclusions: Molecular imaging of mammary tumors in PyMT is precocious, precise, and
predictive. [18F]FDG-PET and [99mTc]TEC SPECT monitor tumor response to chemotherapy.
Key words: Molecular imaging, Biomarker, Breast cancer, Response to treatment, Transgenic
model, Sodium-iodide symporter
Introduction
The ability of in vivo imaging to recognize tumors in a
precocious, precise, and predictive manner improves detec-
tion, staging, and response to treatment of cancer. Animal
models of cancer can be useful to test imaging methods for
tumor progression and response to treatment in longitudinal
studies. However, physiological differences between species
in drug metabolism, circulation, plasmatic concentration of
metabolites and nutriments, etc. may influence imaging
results and may reduce the clinical interest of translational
studies, especially in models where tumors grow in a
xenogeneic environment and/or heterotopically. Transgenic
models have the strengths that tumors develop in situ in the
native tissue, although tumorigenesis is often a slow and
stochastic process, which may render difficult and tedious
the constitution of homogeneous groups of animals for
comparison purposes.
The transgenic mouse model of mammary carcinoma
caused by expression of the polyoma middle T oncoprotein
(PyMT) in the mammary epithelium [1] mimics the Luminal
B type of human breast cancer. Although it does not
recapitulate all of the human disease (absence of bone and
brain metastases, loss of hormone receptors during progres-
sion), it offers several advantages for imaging studies of
breast carcinogenesis: (i) tumors develop rapidly (2–
3 months) in the mammary glands localized along para-
sagittal lines in the neck, chest, abdomen, and pelvis parts,
(ii) penetrance of the phenotype is ~100 % in heterozygous
PyMT+/− female mice, (iii) progression to malignancy offers
similarities with that observed during human ductal carci-
noma carcinogenesis [2], including frequent occurrence of
lymph node and lung metastases at late stages [2], and (iv)
PyMT tumors express many of the genes overexpressed in
human luminal tumors, including estrogen and progesterone
receptors (ER and PR positive) and the sodium-iodide
symporter (NIS) [3]. In the present study, we applied in
vivo imaging techniques for the assessment of early tumor
response in female PyMT mice. We performed X-ray
computed tomography (CT), positron emission tomography
(PET) with 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG)
and 3'deoxy-3'-[18F]fluorothymidine ([18F]FLT), single
photon emission computed tomography (SPECT) with
[99mTc]TcO4 ([
99mTc]TEC), and fluorescent confocal
endomicroscopy (FCE) of microvessels in longitudinal
weekly follow-up to detect mammary tumors and lung
metastases [1]. In vivo imaging was repeated in groups of
animals receiving standard chemotherapy for breast cancer:
doxorubicin, an anthracyclin, or docetaxel, a taxane. In vivo
imaging data were correlated with immunohistochemistry of
Ki-67 and NIS expression.
Material and Methods
Animals
Animal experiments were approved by the local ethical committee
and followed the ARRIVE guidelines of the National Centre for the
Replacement, Refinement, and Reduction of Animals in Research
(London, UK). Female heterozygous PyMT−/+ mice were obtained
by crossing wild-type FVB females with heterozygous PyMT−/+
males. Offsprings were genotyped by qualitative PCR. ADN was
extracted from 25 mm3 of mouse tail using 100 μL of Extract-N-
Amp™ PCR ReadyMix™ incubated for 10 min at 25 °C followed
by 3 min at 95 °C. Primers were PyMT3/PyMT and PO up/PO low
for transgenic and FVB, respectively.
Animals were housed separately at constant temperature (21 °C)
and relative humidity (60 %) under a regular light/dark schedule.
Food and water were freely available. Mice were randomly
assigned to the untreated or treated group. Mean total tumor
volume (TTV) per mouse was defined as the sum of all tumors
visible in the five pairs of mammary glands in a given mouse.
Imaging was performed weekly in non-fasted mice anesthetized
with 2 % isoflurane. A heat lamp was used to maintain body
temperature. Animals were sacrificed under terminal anesthesia at
14 weeks of age (W14) in the untreated group and at W18 in the
treated groups. In total, 96 animals were used for imaging and
biological experimentations.
Chemotherapy
Preliminary Toxicity Studies In order to determine the maximal
tolerated dose (MTD), the cytotoxic drugs doxorubicin and
docetaxel were administered to two groups of five FVB mice.
Doxorubicin (Doxorubicin®, Teva Pharmaceuticals, France) diluted
in 0.9 % NaCl was injected intraperitoneally (IP) in five mice at a
dose of 10 mg/kg weekly during three successive weeks [4].
Docetaxel (Taxotere®, Sanofi-Aventis, France) was diluted in its
specific excipient and given to two different groups of four mice
either intravenously (IV) or IP at different doses (15, 20, and
30 mg/kg) in three successive administrations at 4-day intervals.
After drug administration, all animals were monitored during
2 months by clinical examination, weight assessment every other
day, and dental examination every week.
In the doxorubicin-treated group treated with a 10-mg/kg dose, a
20 % weight loss with a 15-day nadir was observed. No other
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signs of toxicity were observed, and this dose was deemed
acceptable. In the group treated with 30 mg/kg docetaxel IV, a
20 % weight loss was observed, while in the group treated by
30 mg/kg docetaxel IP, weight loss was 10 % with a 12-day nadir.
However, in the IV-treated group, in two cases, we observed severe
muscular paralysis leading to muscular atrophy 2 weeks after the
first injection, followed by partial recovery at 9 weeks. This side
effect was not observed in the group treated by the IP route.
Considering the possibility of supplementary toxicity due to
anesthesia and in order to perform a longitudinal follow-up, in the
present study, docetaxel was administered IP at 20 mg/kg.
Chemotherapy Protocol for Imaging
Homozygous PyMT mice from the same littermate were randomly
assigned to one of the following groups: (i) sham-treated; (ii) three
IP injections of doxorubicin, 10 mg/kg weekly from W9 to W11;
and (iii) three IP injections of docetaxel, 20 mg/kg every 4 days
from W9 to W10. These regimens improve chemosensitivity in
mouse models of breast cancer ([4] and E. Marangoni and M.F.
Poupon, personal communication).
Four mice from each group were imaged with PET from W8 to
W18, and four mice from each group were imaged with SPECT
from W8 to W18. The administration of cytotoxic drugs was
always performed after the SPECT and PET imaging sessions.
Body weights were recorded two to three times per week. No tooth
loss was observed during the follow-up.
Imaging
CT Whole body CT scans were acquired on the Fast micro-CT
scanner SkyScan 1178 (Skyscan, Kontich, Belgium) operated at
50 keV and a rotational angle of 180° with averaging of 4 and
respiratory gating. Pixel size was 160 μm, and the total scan
duration was approximately 4 min. No contrast medium was
administered.
[18F]FDG-PET Imaging
Image Acquisition It has been reported that isoflurane anesthesia
induces large variations of glycemia in fasted mice but is not a
major confounding factor for reproducibility of [18F]FDG-PET [5].
Therefore, in the present study, [18F]FDG was administered in non-
fasted animals and scanning protocols (time after injection and
duration) were standardized as recommended.
A first group of PyMT mice (n=4) was imaged weekly from W8
to W14 (except for 1 mouse that was also imaged until W16) after
tail vein injection of 7 MBq (200 μCi) of [18F]FDG (Cisbio, Orsay,
France) diluted in 100 μl of a saline solution. Under isoflurane
anesthesia, serial dynamic PET images (60 s×5, 120 s×5, 300 s×3,
600 s×3, 900 s×2) were acquired in a microPET Focus 220 (CTI-
Concorde Microsystems Inc., USA) in 3D mode during 90 min,
starting immediately after the injection of [18F]FDG. Time–activity
curves showed that [18F]FDG uptake increased exponentially and
reached a plateau approximately 50–60 min after injection.
Image Reconstruction and Analysis Images were reconstructed
using OSEM 2D with four iterations and 16 subsets and with a
correction attenuation map calculated from the first images [6].
Dynamic images were analyzed with Anatomist software (SHFJ/
CEA, France) using semi-automatic segmentation software (local
mean analysis method or LMA) [7]. The metabolic tumor volume
(MTV) was assessed as the summed volume of all tumoral
mammary glands showing higher [18F]FDG uptake than the
surrounding tissue.
[18F]FLT-PET Imaging
[18F]FLT Synthesis [18F]FLT was synthesized according to a
procedure slightly modified from Yun et al. [8] and Oh et al. [9].
Briefly, fluorine-18, as dried K[18F]F-K222 complex, was intro-
duced into the precursor 3-N-Boc-5'-O-dimethoxytrityl-3'-O-nosyl-
thymidine (ABX, Germany), in 800 μL of acetonitrile at 165 °C for
1 min. After a rapid purification on a silica cartridge, the O-
dimethoxytrityl and N-Boc protective groups were removed using
aqueous HCl 4 N at 90 °C for 5 min. The final purification was
performed on preparative reverse-phase HPLC, eluted with a
mixture of aqueous 0.9 % NaCl and ethanol (92:8, v/v). [18F]FLT
with chemical and radiochemical purities higher than 95 and 98 %,
respectively, was obtained in a 15 to 20 % radiochemical yield
(decay corrected) with a specific radioactivity ranging from 260 to
330 GBq/μmol (decay corrected).
Image Acquisition Dynamic PET acquisitions were acquired
during 90 min (60 s×5, 120 s×5, 300 s×3, 600 s×3, 900 s×2
images) in four PyMT mice with large tumors (W14) after tail vein
injection of 7 MBq (200 μCi) of [18F]FLT (CEA, Orsay, France)
diluted in 100 μl of saline solution.
SPECT Imaging with [99mTc]TEC
Image Acquisition SPECT images were performed on a one-head
10-cm field-of-view parallel-hole collimator gamma camera com-
bined with a CT scanner (Gamma Imager, Biospace Lab, France),
15 min after tail vein injection of 7 MBq (200 μCi) of [99mTc]TEC
(Cisbio, Orsay, France) diluted in 100 μL of saline solution.
Image Analysis Images were reconstructed using an OSEM 2D
protocol and analyzed with Amira ™ software (FEI, USA).
Mammary tumors in PyMT mice showed a clear higher
[99mTc]TEC uptake than adjacent tissue. They were manually
delineated, and their volume was measured and summed to yield
TTV.
In Vivo Fluorescence Imaging
In vivo fluorescence imaging was performed 15 min after
intravenous injection of 200 μl Dextran-FITC (30 mg/ml), using a
fibered FCE (Cellvizio® Mauna Kea Technologies, France). The tip
of the imaging probe was placed in contact with the abdominal
mammary glands. FVB (n=5) and untreated (n=5) and docetaxel-
treated (10 mg/kg weekly from W9 to W11, n=5) PyMT mice were
imaged. Parameters such as total vessel length, vascular density,
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diameter, and morphology of blood vessels were obtained by image
analysis using ImageCell™ software (Mauna Kea Technologies)
and automatic segmentation [10].
Ex Vivo Analysis
Whole Mount In order to assess the tumor diffusion and detect the
lymph node involvement, mammary glands were analyzed using
the whole mount method. They were defatted, dehydrated, and
stained with hematoxylin following the Rosen Laboratory Mam-
mary Gland Whole Mount Protocol [11].
Histology Ki-67 and NIS staining were assessed on formalin-fixed
paraffin-embedded tissues of normal and tumoral mammary glands,
respectively, in FVB and PyMT mice, at W4, W6, W8, W10, W11,
W12, and W14 (n=2 for each time point) and in the treated groups.
Mammary tumors were excised, fixed in 10 % paraformaldehyde in
phosphate-buffered saline (PBS, pH 7.4), dehydrated, and embed-
ded in paraffin. Serial sections were cut at 5 μm and stained with
hematoxylin-eosin or processed for immunochemistry.
Immunohistochemistry Paraffin-embedded sections were depar-
affinized and rehydrated through graded alcohols. Endogenous
peroxidases were blocked with 3 % H2O2 during 5 min at 25 °C in
Tris-buffered solution, washed, and processed for antigen retrieval
with PBS (10 mM, pH 6) in a microwave oven (20 min, 750 W).
For Ki-67, sections were incubated with a goat anti-Ki-67
polyclonal IgG (Sc-7846, Santa Cruz Biotechnology Inc., Santa
Cruz, USA) as primary antibody and a horse anti-goat IgG (PI-
9500, AbCys) as secondary antibody, both at a concentration of
1:300 in 0.5 % Tween-PBS. For NIS, sections were incubated with
a polyclonal rabbit anti-NIS at a concentration of 1:200. To reduce
non-specific interactions of secondary antibodies, tissues were first
incubated with 5 % normal serum from the host before incubation
at 25 °C for 1 h with the primary antibodies. Endogenous
peroxidases were blocked with 3 % H2O2 in water, and immuno-
complexes were visualized by the ABC peroxidase method after
staining with DAB for 2 min (Sigma-Aldrich, USA) and counter-
stained with hematoxylin-eosin. All histological slides were
analyzed by an experienced pathologist (EM). In selected areas of
hyperplasia, adenoma, and carcinoma localized in mammary glands
using HES staining, the Ki-67 index was measured by eye-counting
on 500–1,000 cells.
Tumor Growth Models Modelling of tumor growth was
performed with Monolix 3.1 Release 2 (http://software.monolix.-
org/), a non-linear mixed effect model program that estimates both
the structural model parameters as well as the between-subject
(mice) and residual variability [12].
Statistical Analysis A nonparametric Mann–Whitney test was
used for comparisons of MTV between groups: treated vs. untreated
and doxorubicin- vs. docetaxel-treated. P values of 0.05 or less
were considered statistically significant.
Results
Time Course of Tumor Progression and Detection
by In Vivo Imaging
Ex Vivo Pathology Whole mounts of excised tumoral
mammary glands showed small foci of epithelial tumors as
early as W4 (Fig. 1a). By W7–W8, all PyMT mice presented
epithelial tumors of the mammary gland (Fig. 1b). Tumors
appeared initially in the peri-areolar area and progressed
throughout the mammary glands in a multifocal pattern
along the ductal structures (Fig. 1a–c). Tumors extended
readily and involved the whole gland by W10 (Fig. 1d).
CT and [18F]FDG Imaging W8 corresponded to the
earliest time point at which the tumors could be detected
by palpation. CT images had a low tumor-to-background
ratio and did not detect mammary tumors until they
reached a size sufficient to modify the body contours of
the mice (W14). In contrast, mammary tumors were
detected on PET images as early as W8, as shown in a
series of representative [18F]FDG-PET images acquired
weekly from W8 to W16 in one mouse (Fig. 2). Mean
MTV per mouse increased from 0.76±0.59 cm3 at W9 to
7.45±0.26 cm3 at W14, in a two-phase pattern: a slow
growing phase from W8 to W11 followed by a fast
growing phase thereafter. By W14, tumors had grown to
large sizes and [18F]FDG-PET showed an hypometabolic
central area (see the close up at W14 in Fig. 2) that ex
vivo macroscopy confirmed to be necrosis. Lung
Fig. 1 Spontaneous multifocal tumoral progression. Hematoxylin-stained whole mount sample of mammary glands from
untreated PyMT mice at a W4, b W7, c W9, and d W10. Arrows point to the lymph node (LN) in the center of the mammary
gland.
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metastasis could not be clearly identified in vivo by CT
or PET, but a PET signal above background, possibly
masking the uptake in small pulmonary lesions, was
noted in the mediastinum, in addition to the myocardial
uptake.
[18F]FLT Imaging and Comparison with Ki-67 We found
no contrast between the mammary tumors and the surround-
ing tissue of PyMT mice at 10 min (Fig. 3a) and 30 min
(Fig. 3b) after [18F]FLT injection. Only background activity
and tracer accumulation in the bladder were observed in
images acquired at 30 min or at later times, up to 90 min
after injection. Since [18F]FLT-PET is expected to reflect
proliferation that is likely to be high during tumor
development in the PyMT mice, we searched for the
proliferation marker Ki-67 in serial histological sections of
tumoral mammary glands of PyMT mice, at different stages
of development.
Areas of hyperplasia, adenoma, and carcinoma were
observed in mammary tumors, as previously described by
Lin et al. [2]. Adenoma and carcinoma were present at
W10 (Fig. 3c, d). The Ki-67 index was higher in
carcinoma than in adenoma and hyperplasic areas
(mean±SD of 44±15, 34±12, and 25±11 %, respectively)
(Fig. 3c), and the cell density increased from W10 to
W14 (Fig. 3d–f). The tumor proliferative activity
assessed by the Ki-67 index was high at W14, with
more than 40 % positive cells (Fig. 3c). Therefore, the
absence of contrast on the [18F]FLT images cannot be
attributed to the absence of proliferation in mammary
tumors of PyMT mice. It is noteworthy that mammary
glands of normal FVB mice showed at puberty (W4–W7)
a median Ki-67 index of 6±7 %, in agreement with
ductal hyperplasia during pubertal mammary growth.
SPECT Imaging with [99mTc]TEC SPECT imaging with
[99mTc]TEC showed uptake in the mammary tumors of
PyMT mice as early as W6 yielding clear contrast
throughout to W14 (Fig. 4a). The mean TTV increased
from 0.2±0.2 to 7.5±0.7 cm3 between W9 and W14. The
tumor-to-background ratio was lower on [99mTc]TEC
SPECT images than on [18F]FDG-PET images. Staining of
normal mammary glands for NIS showed an intense and
ubiquitous labeling of the ducts (Fig. 4b), while in tumors,
NIS was present in ductal as well as hyperplasic structures
both on the plasma membrane and in the cytoplasm. NIS
staining of tumoral tissue was more pronounced at W8
before treatment (Fig. 4c) than at W12 after treatment
(Fig. 4d). Lung metastases were not detected on the SPECT
images. To check whether this may have been the
consequence of a low imaging contrast due to high
background in the thoracic area (mediastinum and heart),
we performed ex vivo autoradiography of lungs sampled
after SPECT imaging. Interestingly, [99mTc]TEC uptake was
found in some lung metastases but absent in other metastases
(Fig. 4e, f), although at the cellular level, NIS expression
was observed in all lung metastases at a level similar to that
found in primary mammary tumors (Fig. 4g, h).
In Vivo Fluorescence Imaging of Blood Vessels With
respect to normal mammary glands of FVB mice (Suppl.
Fig. 1a), increased vascular densities and increased blood
vessel diameters were clearly evident in the tumoral glands
of PyMT mice injected with the vascular dye FITC-dextran
and observed by FCE (Suppl. Fig. 1b). However, the
parameters (mean vessel density, vessel length, and diame-
ter) derived from the FCE images were widely variable,
which precluded the use of FCE imaging as a quantitative
tool for assessment of therapy efficacy in this model.
Fig. 2 Longitudinal follow-up of tumor progression from W8 to W16 with [18F]FDG-PET. a Whole body coronal slices of a
untreated PyMT mouse and b zoomed views of the thoracic mammary tumors (numbers indicate age in weeks). Note the
hypometabolic central area indicating necrosis at W14–W16.
J.-L. Alberini et al.: Multimodal Imaging of PyMT Mammary Tumors 621
Assessment of the Response to Chemotherapy
Ex Vivo Pathology and Histology Histological whole
mounts of mammary glands obtained from animals treated
by weekly injections of 10 mg/kg doxorubicin at W9, W10,
and W11 evidenced a clear regression of the lesions between
W10 (Suppl. Fig. 2a) and W12 (Suppl. Fig. 2b) followed by
recurrence at W14 (Suppl. Fig. 2c). In both doxorubicin- and
docetaxel-treated groups, areas of tumor regression with
nodular, scar, and fibrotic tissue and infiltration of inflam-
matory cells were observed at W10. Hyperplasic and
carcinoma lesions resumed after discontinuation of chemo-
therapy, somewhat earlier in the docetaxel than in the
doxorubicin group (W13 vs. W15). This difference might
be explained by the shorter chemotherapy course for
docetaxel than for doxorubicin (8 vs. 14 days), as suggested
by the MTV growth curve showing earlier recurrence in the
docetaxel group (see below).
[18F]FDG Chemotherapy had a major effect on MTV
measured with [18F]FDG in mammary tumors (Fig. 5a). In
contrast to untreated animals in which MTV increased
continuously to reach maximal values at W14, MTV in
animals treated from W9 to W11 by doxorubicin or docetaxel
remained at pretreatment levels over the duration of
chemotherapy and until 3 weeks after its discontinuation until
W13–W14 (Fig. 5b). Mean MTV was 0.18±0.22 and 0.08
±0.16 cm3 at W9 and 0.86±0.98 and 1.29±1 cm3 at W14 in the
doxorubicin- and docetaxel-treated groups, respectively
(Fig. 5b). The change in MTV was statistically different
between doxorubicin-treated group and untreated group
(p=0.028), docetaxel-treated group and untreated group
(p=0.03) and not between treated groups (p=0.84).
After treatment discontinuation, MTV resumed its in-
crease between W14 and time of euthanasia at W16-17, with
a rate of increase in the treated group similar to the one
measured in the untreated group between W11 and W14.
Tumor Growth Analysis Different tumor growth models,
including a Gompertz model, were tested to fit MTV derived
from [18F]FDG-PET. Tumor growth was modeled as
follows: MTV=MTV0·e
kt, where MTV0 is the extrapolated
volume at time 0 (i.e., at W8 when tumors were first
observed with PET), a proportional term to equilibrate the
equation dimension and was fixed to 0.03 cm3 for the
analysis, k is the time constant rate, t is the observation time
in weeks, and the growth half-life is T1/2=log(2)/k. The
between-subject variability was modeled as an exponential
error model and the residual variability as a combined
Fig. 3 Coronal PET views acquired a 10 min and b 30 min after injection of [18F]FLT, showing the absence of tracer uptake in a
PyMT mouse presenting large mammary tumors at W14. c Ki-67 index increases with tumor progression and is higher (35 % or
more) in carcinoma areas than in adenoma and hyperplasic areas (mean from two PyMT mice at each time point). Increase in
tumor cell density and proliferation demonstrated by Ki-67 staining of mammary glands in PyMT mice at d W10, e W12, and f
W14. Scale bars 200 μm.
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(proportional plus constant) error model. The k estimates (%
relative standard errors) were significantly different for the
three groups: 0.315 (4 %), 0.145 (27 %), and 0.212 (36 %)
week−1, yielding T1/2 of 2.2, 4.8, and 3.27 weeks in the
untreated, doxorubicin, and docetaxel groups, respectively.
SPECT At 1 week (W10) and 2 weeks (W11) after
initiation of chemotherapy with docetaxel and doxorubicin,
the TTV of [99mTc]TEC uptake was unchanged or reduced
with respect to pretreatment volumes. During the same time
period, the TTV increased in untreated animals (Fig. 5c).
Discussion
Clinically, 70–80 % of breast cancer patients respond to
neoadjuvant chemotherapy, but a complete response is
found in only 20–30 % [13–15]. Therefore, it is
important to assess response to neoadjuvant drug therapy
as early as possible in order to avoid unnecessary drug
exposure. Functional and metabolic properties of tissues,
including tumors, respond more rapidly than gross
anatomy to changes in the environment; therefore,
functional and molecular imaging modalities likely to
monitor tumor response to treatment more precociously
than tumor size are an important field in cancer research.
Because they are based essentially on the same techni-
ques than clinical imaging, small animal imaging devices
are able to provide longitudinal follow-up in preclinical
studies of new anticancer drugs [16]. Here, we compared
the ability of several imaging methods to document the
natural course of mammary tumor development in PyMT
mice. We then tested the ability of standard imaging
observables derived from these methods to document
precociously, precisely, and predictively the response to
chemotherapy.
Fig. 4 a Serial SPECT images after [99mTc]TEC injection of a PyMT mouse from W5 to W14 (numbers indicate age in weeks).
Sg salivary glands, Th thyroid gland, Tr mammary tumor, Bl bladder. Note [99mTc]TEC uptake in the tumoral mammary glands
already at W6. b–d Immunohistochemistry of NIS of the mammary gland in a FVB mouse at b W8 and in tumoral mammary
glands of PyMT mice at c W8 and d W12; scale bars 50 μm. e Ex vivo autoradiography of lung in a PyMT mouse at W15 after
administration of [99mTc]TEC. [99mTc]TEC is present in some lung metastases (white arrow) and f absent in other metastases
staining positively for NIS as shown with black arrows. g, h Immunohistochemistry showing NIS labeling of the plasma
membrane in lung metastases.
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How Precocious Is Detection of Cancer by In Vivo
Imaging in PyMT?
CT was able to detect the mammary tumors of the PyMT
mice reliably only at W14–W15. CT is not well adapted to
follow mammary carcinoma in mice because of a lower soft
tissue contrast in small animals than in humans. In contrast,
[99mTc]TEC-SPECT and [18F]FDG-PET imaging showed a
significant tumor-to-background contrast as early as W6 and
W8, respectively (Fig. 4 or 2 and Suppl. Fig. 3), supporting
the use of molecular imaging for early tumor detection in
PyMT mice. The remarkably precocious contrast visible
with [99mTc]TEC-SPECT at W6 could be explained by the
high overexpression of NIS in premalignant hyperplasic
structures. Both [99mTc]TEC and [18F]FDG were able to
follow tumor progression in the PyMT model from early
stages on, even though at later stages, [99mTc]TEC uptake as
well as NIS staining tended to decrease in advanced breast
cancer lesions, in contrast to [18F]FDG measurements of
MTV that increased until the end of the period of
observation.
How Precise Is Detection of Cancer by In Vivo
Imaging in PyMT?
BPrecise^ imaging of cancer can mean one of two different
things: (i) images that provide quantitative values of a
cancer-specific molecular or functional hallmark or (ii)
images that are proper surrogate markers of cancer
progression.
Concerning the first aspect, in the present study,
[18F]FDG-PET and [99mTc]TEC-SPECT in PyMT mammary
tumors showed increased metabolism and NIS expression,
respectively. In contrast, [18F]FLT-PET did not reflect well
the proliferation of tumor cells evidenced by Ki-67 labeling.
Discrepancies between in vivo [18F]FLT uptake and prolif-
eration have been reported in animal studies and explained
by competition for [18F]FLT uptake by the high serum levels
of thymidine in mice and the existence of a thymidine
salvage pathway of variable importance between species and
strains [17, 18].
Concerning the second aspect, LMA segmentation of
PET dynamic images excluded the tumor regions with
[18F]FDG concentrations not higher than background tissue.
These regions often referred to as Bnecrotic^ in animal
studies were observed from W12 in the tumor cores of
untreated mice and correspond to non-viable tumor tissue.
Assessment of MTV with PET excludes these regions from
the measurement of the tumor volume and improves the use
of mathematical models of tumor growth and response to
chemotherapy.
The size of the tumor began to increase exponentially
starting at W10–11. FCE showed that this period coincides
with a sudden change in the aspect of the tumor vessels and
corresponds to the onset of the angiogenic switch [19],
known to be associated with the progression towards
carcinoma in this model [20].
Fig. 5 [18F]FDG-PET and [99mTc]TEC-SPECT show reduced tracer uptake with chemotherapy. a Typical [18F]FDG-PET scan at
W13 in an untreated (left) and a doxorubicin-treated (right) PyMT mouse. b Longitudinal assessment of the total metabolic
tumor volume delineated by automatic segmentation from W8 to W14 in untreated (blue curve) and from W8 to W17 in
doxorubicin- (red curve) and docetaxel-treated (green curve) PyMT mice (n=4 for each group); tumor volumes are in cubic
centimeter. Data points are mean±SD of four independent measurements. c Same for [99mTc]TEC uptake on SPECT images;
tumor volumes are shown as percentage of the volume at W9.
Table 1. Strengths and weaknesses of the PyMT model
Strengths (≈ similarities with human disease)
Orthotopic (mammary gland) and in situ (ductal) tumors
Rapid: 2–3 months
Reproducible: 100 % penetrance in female homozygotes
Immune competent animals
Tumor development mimics human mammary carcinogenesis stages
Expresses many markers of breast cancer including hormone receptors
Lung and lymph node metastases
Weaknesses (≈ difference with human disease)
Genetic, not environmental etiology
Multifocal tumors with different stages
No brain or bone metastases
Juvenile disease
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How Predictive of the Response to Chemotherapy
Is In Vivo Imaging in PyMT?
[18F]FDG-PET The effects of doxorubicin and docetaxel
were assessed by measuring the metabolic tumor volume derived
from in vivo images, each animal serving as its own control, a
crucial point considering the inter-individual variability of tumor
growth [5, 16]. Drugs were administered to PyMT mice at W9,
1 week after mammary tumors had become palpable. From this
point of view, the present study reflects somewhat the clinical
situation where imaging is challenged to report on the effect of
drugs after diagnosis and before surgery.
Administration of two drugs commonly used in neo-
adjuvant breast cancer treatment [13–15] induced a pro-
longed delay of the increase in [18F]FDG uptake in the
mammary tumors, at the expense of some toxicity. The ex
vivo whole mount results combined with those of in vivo
[18F]FDG-PET imaging support the view that MTV assessed
using [18F]FDG were related to tumor regression and not to
cellular stunning after administration of cytotoxic drugs. The
difference between the doxorubicin group and the docetaxel
group could be related to the nature of the drug, the dosage,
or the duration of administration (14 vs. 8 days for
doxorubicin and docetaxel, respectively).
Overall, our results support small animal [18F]FDG-PET
for the assessment of response to chemotherapy, with the
limitation that, as can be expected in a transgenic model in
which tumorigenesis is genetically encoded, tumor progres-
sion resumes after chemotherapy discontinuation.
NIS-[99mTc]TEC SPECT Imaging NIS is a membrane
glycoprotein of the follicular thyroid cells that actively
transports iodine used for thyroid hormone biosynthesis. NIS
was shown to be overexpressed in human breast cancers
[21–23] and in several transgenic mice models including
PyMT [21]. NIS overexpression was observed by immuno-
histochemistry in human breast cancers but not in normal
tissue in a small series of samples [21] and confirmed in a
larger series of 371 samples assessed by microarrays and
histological techniques [22].
Surprisingly, in the present results, NIS overexpression
was observed in normal mammary ducts in FVB mice, using
three different immunohistochemical methods. This obser-
vation is not in agreement with the SPECT images showing
[99mTc]TEC uptake only in mammary tumors and not in
normal mammary glands. Although NIS expression was
more heterogeneous and at a lower level in mammary
tumors than in normal breast ducts (Fig. 4), the higher
cellular density in tumors than in normal mammary glands
induced a higher contrast with the surrounding tissue.
Although lung metastases are frequent in PyMT mice,
confirmed by macroscopic analysis, the absence of
[99mTc]TEC uptake in some lung metastases on ex vivo
autoradiography suggested the loss of NIS expression in
metastatic lesions. Moreover, although radionuclide uptake
has been shown to be correlated with NIS levels, cell surface
NIS levels are variable in breast tumors [23].
The PyMT Transgenic Mouse as a Model to Study Mammary
Cancer With In Vivo Imaging Carcinogenesis in the PyMT
mouse presents similarities with that of human breast cancer
subtype with a multistep progression from an initial hyper-
plasic stage to invasive carcinoma [2]. Up to a certain extent,
this animal model is relevant for dynamic studies of disease
evolution and therapeutic intervention and its limitations are
summarized in Table 1. A main difference with human
disease is the occurrence of multiple points of tumor
initiation at different stages ranging from hyperplasia to
carcinoma. Cancer growth occurs during puberty in PyMT
mice, and at advanced stages (W10 to W16), each mouse
presents several tumoral foci on each mammary gland.
However, from the imaging point of view, this drawback can
be limited by the use of MTV and TTV to quantify
[18F]FDG and [99mTc]TEC, respectively.
Conclusion
In vivo molecular imaging of the PyMT mouse model of
breast carcinoma by [18F]FDG-PET and [99mTc]TEC
SPECT is a precise tool to allow longitudinal monitoring
and predict the tumor response to chemotherapy
precociously.
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